Long-term effects of neonatal glucocorticoid treatment on health in later life (follow-up study)

Long-term effects of neonatal glucocorticoid treatment on health in later life (follow-up study) - Long-term effects of neonatal glucocorticoid treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33574

Enrollment

240

Registered

2009-03-03

Start date

2009-04-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aandoeningen ontstaan in de perinatale periode long-term effects of neonatal glucocorticoid treatment

Interventions

None listed

Eligibility

Age

12 Years to 17 Years

Inclusion criteria

Inclusion criteria: Inclusioncriteria glucocorticoid treated groups: - Gestational age

Exclusion criteria

Exclusion criteria: Exclusioncriteria glucocorticoid treated groups: - Dysmaturity - Glucocorticoid treatment for other indication (i.e. hypotension) or incomplete course - Intraventricular hemorrhage > grade II according to Papile - Major congenital anomalies - Periventricular leukomalacia - Language barrier;Referencegroup: - Dysmaturity - Glucocorticoid treatment for other indication (i.e. hypotension) - Intraventricular hemorrhage > graad II according to Papile - Major congenital anomalies - Periventricular leukomalacia - Language barrier

Design outcomes

Primary

Measure	Time frame
The proposed study will provide data on behavioral, neuropsychological, and motor function. Secondly, basal physiological function (HPA-axis, and immune, cardio-vascular and central nervous system function), markers for cardio-vascular, renal and metabolic disease, and pain sensitivity will be evaluated. Finally, we will determine stress-induced HPA-axis, cardiovascular system and central nervous system responses. Blood cells will also be saved to isolate DNA to perform epigenetic studies in the future.	—

Measure

Time frame

The proposed study will provide data on behavioral, neuropsychological, and motor function. Secondly, basal physiological function (HPA-axis, and immune, cardio-vascular and central nervous system function), markers for cardio-vascular, renal and metabolic disease, and pain sensitivity will be evaluated. Finally, we will determine stress-induced HPA-axis, cardiovascular system and central nervous system responses. Blood cells will also be saved to isolate DNA to perform epigenetic studies in the future.

—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results